Benefit‐Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

On April 27, 2017, the U.S. Food and Drug Administration approved regorafenib for the treatment of patients with advanced hepatocellular carcinoma (HCC) who had previously been treated with sorafenib. Approval was based on the results of a single, randomized, placebo‐controlled trial (RESORCE) that...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncologist
Hlavní autoři: Pelosof, Lorraine, Lemery, Steven, Casak, Sandra, Jiang, Xiaoping, Rodriguez, Lisa, Pierre, Vadryn, Bi, Youwei, Liu, Jiang, Zirkelbach, Jeanne Fourie, Patel, Anuja, Goldberg, Kirsten B., McKee, Amy E., Keegan, Patricia, Pazdur, Richard
Médium: Artigo
Jazyk:Inglês
Vydáno: AlphaMed Press 2018
Témata:
Regulatory Issues: FDA
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5896719/
https://ncbi.nlm.nih.gov/pubmed/29386313
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0422
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky